Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, May 23, 2025
/PRNewswire/ -- Equity Insider News Commentary – A
new report from Philips reveals a growing divide between
doctors and patients when it comes to AI in healthcare. While 63%
of surveyed healthcare professionals believe AI can help improve
outcomes, only 48% of patients share that optimism. As researchers
explore what's needed for successful AI adoption in healthcare,
major players in tech and biotech are already moving ahead—recent
updates have come from Avant Technologies, Inc. (OTCQB:
AVAI), Renovaro Inc. (NASDAQ: RENB), Certara, Inc.
(NASDAQ: CERT), CareCloud, Inc. (NASDAQ: CCLD), and
Microsoft Corporation (NASDAQ: MSFT).
Analysts at MarketsandMarkets expect the AI healthcare
sector to grow at a 38.6% CAGR, topping $110
billion by 2030. Accenture goes even further,
estimating AI could inject another $461
billion in added value by 2035—amplifying impact across a
global healthcare system already on track to surpass $2.26 trillion.
Avant Technologies, Inc. (OTCQB: AVAI), in partnership
with Ainnova Tech, is positioning its Vision AI platform at
the forefront of predictive healthcare. The company is in advanced
discussions to acquire or exclusively license a patented early
disease detection technology that could significantly enhance its
diagnostic capabilities. If finalized, the deal would allow Vision
AI to generate clinical insights even in the absence of a complete
patient dataset—unlocking earlier intervention opportunities and
supporting a more proactive model of care.
"Our purpose is to create the future of early disease detection
in an accessible way, so that patients can get a preventive
check-up anywhere, at a low cost, and easily," said Vinicio Vargas, CEO at Ainnova and member
of the Board of Directors of the joint venture company, Ai-nova
Acquisition Corp. (AAC), said of AAC's aim to continue
to add to its portfolio. "We want to prevent patients with risk
factors from developing other diseases that could have been avoided
before they became a real problem. To this end, we are seeking to
integrate new technologies into our portfolio within a single
platform, both through our R&D efforts and through potential
exclusive licenses or acquisitions."
The potential acquisition aligns with Avant and
Ainnova's shared mission to deliver scalable, preventive
health tools that merge retinal imaging, vital sign monitoring, and
machine learning into one streamlined platform. Vision AI is
already positioned as a next-generation diagnostic engine for
chronic conditions like diabetes, cardiovascular disease, and
kidney dysfunction. Now, the joint venture is pushing
further—evaluating breakthrough technologies that could detect
emerging health issues at a pre-symptomatic stage.
Recent platform updates saw four proprietary algorithms—trained
on over 2.3 million real-world clinical cases—fully integrated into
Vision AI. The addition of new IP from this proposed deal would
mark a significant leap forward, enabling predictive models to
extract meaningful signals from even limited patient data.
Avant and Ainnova view this initiative as
part of a broader strategy to consolidate breakthrough tools that
make early disease detection more scalable, mobile, and applicable
across diverse healthcare settings. While a final agreement has yet
to be announced, the companies have stated they will keep
shareholders informed as developments progress.
In parallel, Avant has entered formal discussions to
acquire Ainnova outright—building on their existing
alignment under the Ai-nova Acquisition Corp. (AAC)
structure. The timing is deliberate, coming just ahead of a planned
FDA pre-submission meeting this July. A completed merger
would unify operations, reduce internal complexity, and bolster the
joint venture's regulatory readiness as it prepares for potential
U.S. market entry.
"We believe bringing the two companies together will offer
tremendous value for shareholders," said Vargas. "It will simplify
the process of advancing our technology to market, and it will
deliver value to our customers and partners as we promote our
technology portfolio globally."
At the center of this initiative is Vision AI—a non-invasive
screening platform that integrates retinal imaging, vital sign
monitoring, and machine-learning models to flag early indicators of
chronic disease. The system targets conditions such as diabetic
retinopathy, cardiovascular issues, kidney and liver disorders, and
type 2 diabetes. Operated under the AAC structure, the joint
venture holds global rights to Vision AI, which has demonstrated
over 90% sensitivity in early detection based on research cited by
the NIH.
"This milestone reflects our two-tiered strategy, rapid
deployment in low-regulation markets where Vision AI operates as a
screening tool, and simultaneous progress toward FDA
clearance for the U.S. market," said Vargas. "Entering the U.S.
will unlock significant commercial potential, and early engagement
with regulators ensures we do so with speed, credibility, and a
validated product."
While many AI healthcare platforms remain stuck in pilot stages,
Avant's Vision AI is already live across multiple Latin
American markets—including Chile,
Mexico, and Brazil—where it's actively being used in
clinical settings. These real-world deployments are generating
essential data on safety and efficacy, while also providing user
feedback that guides ongoing system improvements.
To broaden its diagnostic reach, the Ai-nova joint venture
recently integrated four additional algorithms into the platform.
Each was trained on a dataset of more than 2.3 million clinical
records, enhancing Vision AI's precision across a wider spectrum of
chronic diseases. With active momentum abroad and U.S. regulatory
discussions now underway, Avant's trajectory appears to be
moving from early validation toward broader market penetration.
CONTINUED... Read this and more news for Avant
Technologies at:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Renovaro Inc. (NASDAQ: RENB) has officially launched
Augusta, a next-generation AI-powered platform targeting precision
neurology. Designed for patient stratification, biomarker
discovery, and accelerated drug development, Augusta integrates
multiomics, contingent AI, phenoclustering, and in silico screening
into one modular system.
"The Augusta platform is about validation," said David Weinstein, CEO of Renovaro Inc.
"We're setting a new bar for how AI can be responsibly and
effectively deployed in clinical and experimental settings."
The platform has already demonstrated early success in
Parkinson's disease and epilepsy, with expansion plans underway for
additional neurological conditions.
Certara, Inc. (NASDAQ: CERT) has launched its
Non-Animal Navigator™ solution to help drug developers reduce
reliance on animal testing, aligning with the FDA's Roadmap
to Reducing Animal Testing in Preclinical Safety Studies.
"The FDA announcement and roadmap pave the way for more
model-informed drug development approaches that are predictive,
efficient, and ethical," said William F.
Feehery, CEO of Certara Inc. "It is part of a growing
industry adoption trend to use scientifically robust new approach
methodologies (NAMs) like AI-enabled biosimulation to improve
strategic decision-making and success rates at every phase of drug
development."
The new offering combines strategic regulatory guidance with
AI-enabled biosimulation, providing an ethical and efficient
pathway through early-stage drug development. With adoption already
underway, Certara's platform offers a future-ready model for
companies advancing biologics, including monoclonal antibodies and
ADCs.
CareCloud, Inc. (NASDAQ: CCLD) has been named
Maxim Group's "Top Healthcare IT Pick for 2025," with
analysts citing the company's AI-first strategy, strong financial
performance, and discounted valuation as key drivers.
"AI is now deeply integrated into our operations—from
documentation and revenue cycle management to patient engagement
and analytics," said Hadi Chaudhry,
Co-CEO of CareCloud Inc. "This is not an add-on, it is a
foundational capability that is changing how healthcare is
delivered and experienced."
The firm recently launched its AI Center of Excellence and
introduced purpose-built tools like cirrusAI Notes and cirrusAI
Voice to streamline clinical workflows and improve patient
engagement. CareCloud plans to scale its AI team from 50 to
500 by year-end, deepening its role as a leader in applied
healthcare AI.
Microsoft Corporation (NASDAQ: MSFT) has introduced
its healthcare agent orchestrator—a multi-agent AI framework
designed to support complex clinical workflows, such as tumor
boards, by analyzing multimodal data across imaging, genomics, and
electronic health records.
"The vision of the healthcare agent orchestrator is to rapidly
surface, summarize, and take action on relevant multimodal medical
information for each complex cancer case, so hours of review can
become minutes," said Dr. Joshua
Warner, Radiologist at UW Health and Assistant Professor of
Radiology, UW School of Medicine and Public Health.
"Collaborating with Microsoft allows us to explore the value
of these models for tumor boards and beyond."
Now available through Azure AI Foundry, the system enables
clinicians and developers to coordinate specialized AI agents
directly within Microsoft Teams and Office tools, streamlining
hours of expert analysis into minutes. Leading institutions like
Stanford, Johns Hopkins, and Providence are already piloting the
technology to accelerate cancer diagnosis, clinical trial matching,
and treatment planning.
Source:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
Equity
Insider
info@equity-insider.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
Equity Insider is a wholly-owned subsidiary of Market IQ Media
Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies
Inc. advertising and digital media from the company directly. There
may be 3rd parties who may have shares Avant Technologies Inc., and
may liquidate their shares which could have a negative effect on
the price of the stock. This compensation constitutes a conflict of
interest as to our ability to remain objective in our communication
regarding the profiled company. Because of this conflict,
individuals are strongly encouraged to not use this publication as
the basis for any investment decision. The owner/operator of MIQ
own shares of Avant Technologies Inc. which were purchased in the
open market. MIQ reserves the right to buy and sell, and will buy
and sell shares of Avant Technologies Inc. at any time thereafter
without any further notice. We also expect further compensation as
an ongoing digital media effort to increase visibility for the
company, no further notice will be given, but let this disclaimer
serve as notice that all material disseminated by MIQ has been
approved by the above mentioned company; this is a paid
advertisement, and we own shares of the mentioned company that we
will sell, and we also reserve the right to buy shares of the
company in the open market, or through other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between any predictions and actual results.
Always consult a licensed investment professional before making any
investment decision. Be extremely careful, investing in securities
carries a high degree of risk; you may likely lose some or all of
the investment.
Video -
https://mma.prnewswire.com/media/2695138/Equity_Insider.mp4
Logo
- https://mma.prnewswire.com/media/2644233/5335696/Equity_Insider_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ai-could-add-461-billion-to-global-healthcareand-these-new-platforms-are-leading-the-charge-302464286.html
SOURCE Equity Insider
